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We examined the benefit of tissue plasminogen activator (tPA), delivered as part of usual stroke 
management, on patient-reported outcomes and healthcare utilization.  Using a case control design, 
patients who received tPA as part of usual stroke management were compared with patients who would 
have received tPA had they arrived to the hospital within the therapeutic time window.  Data were 
collected from surveys 6 months post stroke using standardized patient-reported outcome measures 
and questions about healthcare utilization.  Demographic and medical data were acquired from hospital 
records.  Patients were matched on stroke severity, age, race, and gender.  Matching was done with 1:2 
ratio of tPA to controls.  Results were compared between groups with 1-tailed tests due to directionally-
specific hypothesis in favor of the tPA group.   
The tPA (n = 78) and control (n = 156) groups were matched across the variables, except for 
stroke severity, which was better in the control group; subsequent analyses controlled for this 
mismatch.  The tPA group reported better physical function, communication, cognitive ability, 
depressive symptomatology, and quality of life/participation compared to the control group.  Fewer 
people in the tPA group reported skilled nursing facility stays, emergency department visits, and re-
hospitalizations after their stroke compared to controls.  Reports of other post-acute services were not 
different between groups.  While it is known that tPA reduces disability, this is the first study to 
demonstrate the effectiveness of tPA in improving meaningful, patient-reported outcomes.  Thus, use of 
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  The definitive NINDS rt-PA trial showed that persons who received tissue plasminogen activator 
(tPA) were 30% less likely to experience disabling symptoms at 90 days post stroke compared to those 
who had received a placebo.(1)  Economic modeling from this same dataset indicated that the increased 
hospitalization costs associated with tPA are offset by savings from decreased post-acute expenditures, 
including institutionalization.(2)  Additional efforts since have refined our understanding of tPA 
delivery,(3-7) developed national guidelines for use of tPA,(8), and implemented national programs to 
increase and improve tPA use.(9-11)  
  Efficacy data have come primarily from clinical impairment scales, such as the NIHSS, and from 
brief disability scales, such as the modified Rankin Scale, at 90 days post stroke.  While these scales are 
useful for large-scale clinical trials, they fail to capture many outcomes that are meaningful to stroke 
survivors.(12)  Collection of outcome data at 90 days post stroke may be somewhat early, as people 
have just completed post-acute rehabilitation services and have yet to fully return to daily life.(12)  
Effectiveness data, indicating benefits of tPA as part of routine clinical care, have also been collected at 
90 days post stroke and have used the same brief scales.(13-16)  Thus, there are minimal data to 
confirm the effectiveness of routine use of tPA on patient-centered outcomes beyond 90 days post 
stroke.  Given the resources invested at multiple levels across healthcare systems for implementation of 
tPA protocols, it is necessary to understand its effectiveness with respect to the daily lives of stroke 
survivors.       
The purpose of this study was to examine the real-world benefit of tPA, delivered as part of 
usual stroke management, on patient-reported outcomes and healthcare utilization.  This was a 
pragmatic comparative effectiveness study conducted at a large, academic medical center.  Given the 
abundance of efficacy data, we hypothesized that, at 6 months post stroke, persons who received tPA 
would report better function across multiple domains (physical function, cognition, communication), 
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greater return to pre-stroke activities, and lower post-acute healthcare utilization compared to people 
who did not receive tPA.    
  
METHODS 
This study was a retrospective case control analysis of prospectively collected data, comparing 
outcomes in patients who received tPA as part of usual care with patients who would have received tPA 
had they arrived to the hospital within the therapeutic time window, i.e. criteria other than time were 
met.  At present, all persons with a diagnosis of stroke or transient ischemic attack (TIA) from our 
hospital are contacted for a follow-up survey at 6 (± 2 weeks) months after the event.  People with 
stroke have provided informed consent to have their data stored and used for research. Washington 
University Human Research Protection Office has approved the database and studies using de-identified 
data.  This sample includes people who received care at our hospital plus others who received tPA at a 
partner hospital and were transported to our facility for further care.   
Data in this report were collected between February 2011 and October 2013.  Follow-up surveys 
were completed via telephone (47% of sample), mail (33%) or email (21%).  Surveys could be completed 
by the patient or a caregiver.  If a patient experienced another stroke within the 6 month follow-up 
period, the survey was completed 6 months from the new stroke.  No survey data were collected from 
deceased individuals or their caregivers.  Demographic and medical data regarding the stroke were 
acquired from hospital records, including National Institute of Health Stroke Scale (NIHSS)(17) at time of 
initial presentation to the emergency department, age, gender, race, marital status, education level, 
insurance coverage, date of stroke, side of stroke, and pre-morbid Barthel Index.(18, 19)      
Patient-reported outcomes were collected using valid, reliable, standardized questionnaires by 
trained personnel.  Assessments administered were: the Stroke Impact Scale (SIS), a measure of self-
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perceived abilities in multiple domains affected by stroke(20-24); the Patient Health Questionnaire 9-
item version (PHQ-9), a measure of depressive symptomatology; (25, 26) the Reintegration to Normal 
Living Index (RNL), a measure of satisfaction with one’s abilities to engage in daily life (27, 28);  and the 
Modified Rankin Scale, a measure of global disability.(29-31)  Modified Rankin Scale scores were 
dichotomized to those with good outcome (scores of 0 or 1) and those with poor outcome (scores of 2 
or higher).  Additional items in the survey included questions about falls,(32-34) return to driving and 
return to work.(35)  
Healthcare utilization information was collected via self-report.  This was chosen over extracting 
data from administrative records because the utilization records of our stroke population from a large 
geographic area are not contained in one or only a few databases, nor did we want to limit our sample 
to just people covered by Medicare.  Procedures to minimize self-report bias (either over- or under-
reporting) were utilized as much as possible.(36)   Patients reported if they had an inpatient 
rehabilitation facility (IRF) stay, a skilled nursing facility (SNF) stay, utilized home health services (HH), 
utilized outpatient rehabilitation services, the number of physician office visits, visited an emergency 
department, and/or were re-admitted to a hospital after discharge from the initial stroke-induced 
hospitalization.   
tPA was administered according to hospital protocol, largely following the NINDS tPA trial and 
ECASS III trial inclusion/exclusion criteria.(1, 3, 37)  Patients who received tPA and completed 6 month 
surveys were matched to patients with completed surveys who did not receive tPA.  To be considered a 
match, the potential control had to satisfy the medical criteria (1, 3, 37) to receive tPA but arrive to the 
hospital outside of the therapeutic time window (beyond 4.5 hrs).  Patients receiving tPA and controls 
were matched on initial NIHSS score (± 2 pts), age (± 5 yrs), race, and gender.  Matches were only 
searched for within ± 12 months of date of stroke, in case any changes in hospital policies or programs 
had influenced care or outcomes.  Matching was performed using a 1:2 ratio of tPA to controls.  
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Personnel who collected survey data were separate and independent from personnel who assigned 
matches, and each was blinded to the activities and data of the others.     
 Statistical analyses were performed using SAS software (Version 9.3 of the SAS System for Unix, 
SAS Institute, Cary, North Carolina, USA). Descriptive statistics were calculated for all variables.  In order 
to examine how well the tPA and control groups were matched, student’s t-tests were performed to 
compare groups for continuous variables and Chi-squared tests were used for dichotomous variables. 
Because the two groups were not matched for NIHSS score (p=0.002, control < tPA), we adjusted for this 
in subsequent statistical models.  The differences in continuous and nominal outcome variables 
between groups were analyzed by general linear models (PROC GLM). Logistic regression models were 
used for analyses of categorical outcomes.  Statistical significance was set at p < 0.05.   One-tailed tests 
were used due to the directionally-specific hypotheses in favor of the tPA group.  
 
RESULTS 
The overall proportions of people completing the survey are provided in Table 1.  Persons 
receiving tPA completed the survey at the same rate as the entire hospital stroke and TIA population (X2 
= 4.11, p = 0.39), indicating that there was no obvious selective bias in survey responders.  Surveys were 
completed by patients themselves 91% of the time in the tPA group vs. 85% of the time in the control 
group (X2 = 1.68, p = 0.22).  Matched characteristics between the tPA group and the control group are 
shown in Table 2.  Subjects were well matched on age, gender, race, pre-morbid Barthel Index and other 
variables.  Lesion distributions were different between groups with a lower percentage of right sided 
lesions and a higher percentage of lesions classified as unknown in the control group.  The groups were 
unmatched for NIHSS, with increased stroke severity, i.e. higher NIHSS scores, in the tPA group (p = 
0.002).  We therefore controlled for NIHSS in the subsequent analyses.        
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Six-month outcomes from patient self-report and the statistical comparisons between groups 
are provided in Table 3.   Compared to the control group at six months, the tPA group had better 
physical function, cognition, communication, and quality of life/participation (SIS domains).  PHQ-9 
scores indicated less depressive symptomatology in the tPA group, but the difference was small.  People 
in the tPA group had slightly more satisfaction with their abilities (RNL scores), less disability (modified 
Rankin Scores), and reported fewer falls.  The percentage of people who reported returning to driving 
and working were not different between groups, in the smaller subset of people who were driving and 
working pre-stroke.       
Self-reported healthcare utilization data and the statistical comparisons between groups are 
provided in Table 4.  There was a trend toward fewer people in the tPA group reporting a stay in an 
inpatient rehabilitation facility.  A larger proportion of the control group had a post-acute skilled nursing 
home stay.  Use of home health services, outpatient rehabilitation services, and physician office visits 
were similar across groups.  The tPA group reported fewer emergency department visits and fewer re-
hospitalizations in the 6 month period after their stroke.     
 
DISCUSSION  
These data indicate the effectiveness of tPA on patient-reported outcomes and some measures 
of post-acute healthcare utilization at 6 months post stroke.  The magnitudes of the between group 
differences were clinically meaningful for most outcome measures, such as a 12 point difference in 
physical function and a 9 point difference in quality of life/participation on the Stroke Impact Scale.(20)  
Utilization of the more costly healthcare services, i.e. skilled nursing facility stays, emergency 
department visits, and rehospitalizations, were lower in the tPA group.  Our data builds upon previous 
reports of 90-day effectiveness (13-16, 38) to show benefit at 6 months with respect to functional 
domains, quality of life, and healthcare utilization that are important for daily life.       
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We were able to detect clinically-meaningful changes in patient-reported outcomes with a 
relatively small sample size.  While the small sample size and single site limit generalization of results, 
tPA must have a powerful influence on outcomes because its benefit could be detected in patient self-
report measures at 6 months post stroke.  Interestingly, the patient-reported benefit spanned nearly all 
measured domains, such as cognition and communication, and not just physical function.  Effectiveness 
in non-motor domains is an important finding because other tPA effectiveness data have been collected 
with the Modified Rankin Scale, a scale that is nearly entirely focused on disability in the motor 
domain.(39)  Moreover, tPA in this study was delivered as a part of routine clinical care, not via a 
rigorously controlled research protocol.  Our results therefore fully support ongoing efforts to increase 
access to tPA to as many eligible patients as possible.  
The overall proportion of people completing the survey was low (Table 1).  It was difficult to 
reach the more severely affected patients, particularly those permanently institutionalized.  Likewise, it 
was difficult to reach some very mildly affected patients, as they were busy with life and often not 
interested in completing a survey.  Because the rate of completion did not differ in the patients who 
received tPA compared to the overall hospital population, it is probable that any biases introduced by 
low response rates would have a similar effect on both groups.  The low response rates limited our 
ability to detect a difference between groups on the questions of return to driving and return to work.  
These are outcomes that are highly important to patients.  It is not possible to determine if the lack of 
differences seen here is due to a restricted sample for these questions (footnote in Table 3), individual 
patient choices not to return to these activities, or economic reasons, such as lack of a vehicle or job 
opportunities.    
Self-report is an appropriate methodology for collecting longer-term functional outcomes, but is 
less accurate for collecting post-acute healthcare utilization.(36)  An advantage of the self-report 
method is that data are collected regardless of the person’s insurance provider and regardless of where 
9 
 
the person receives services, e.g. the re-hospitalization is counted even if a person with private 
insurance provider is admitted to a different hospital.  Because our facility treats patients with stroke 
from a 5-state catchment area with many different service and insurance providers, it would have been 
impossible to gather these data from administrative records.  The potential for individuals to over- or 
under-report their healthcare utilization is high.  Self-report of salient service utilization in short time 
periods (≤ 6 months) appears to be the most accurate, but specific data regarding who is likely to under- 
vs. over-report are on which services are not clear.(40-42)  The likely effect on our results therefore is 
that there is more noise in the healthcare utilization measures, and not a differential bias of over- or 
under-reporting in one group vs. the other.      
 Despite the potential noise in the healthcare utilization data, we saw a clear difference in 
utilization of some of the more costly post-acute care services.  A lower utilization of services, such as 
skilled nursing facility stays, emergency department visits, and re-hospitalizations would likely translate 
to a lower cost for healthcare services, although a formal cost-effectiveness analysis is beyond the scope 
of this report.  Our healthcare utilization findings build upon the earliest 90-day cost-effectiveness data 
collected in the original randomized controlled trials,(1) to show a sustained benefit of tPA use.    
 A final limitation to consider is that there may have been other factors that influenced stroke 
outcomes and could have accounted for the differences seen here.  One factor may be lesion side, with 
slightly fewer people with right-sided lesions in the control group.  Other possible factors include 
unmeasured variables.  For example, people in the tPA group could have had stronger social support at 
home or better access to transportation that enabled them to arrive at the hospital in time.  These same 
factors could also have facilitated recovery, leading to better outcomes.  While we found no between-
group differences in who completed the survey, marital status, education level, and insurance, these 
simple variables are modest proxies for the complex constructs of socioeconomic status and social 
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support networks.  Additional work is needed to determine to measure social support networks, how 
they change over recovery, and how they influence outcomes.       
    
Conclusions 
While it is known that tPA reduces long-term disability, this is the first study to demonstrate the 
effectiveness of tPA in improving meaningful, patient-reported outcomes, such as physical function, 
cognition, and communication.  These data indicate that use of tPA provides a large benefit to the daily 






1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological 
Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-7. 
2. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of 
tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 
1998;50(4):883-90. 
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with 
alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-29. 
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis 
with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative 
Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017-25. 
5. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind 
placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke 
(ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 
1998;352(9136):1245-51. 
6. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-
type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The 
ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional 
Therapy in Ischemic Stroke. JAMA. 1999;282(21):2019-26. 
7. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated 
within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic 
Stroke. Stroke. 2002;33(2):493-5. 
12 
 
8. Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for 
the early management of patients with acute ischemic stroke: a guideline for healthcare professionals 
from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947. 
9. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients 
with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. Arch 
Intern Med. 2008;168(4):411-7. 
10. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, et al. Get With the 
Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute 
stroke or transient ischemic attack. Circulation. 2009;119(1):107-15. 
11. Cumbler E, Wald H, Bhatt DL, Cox M, Xian Y, Reeves M, et al. Quality of care and outcomes for 
in-hospital ischemic stroke: findings from the national get with the guidelines-stroke. Stroke. 
2014;45(1):231-8. 
12. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic 
review and some recommendations to improve practice. Stroke. 2000;31(6):1429-38. 
13. Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, et al. The iScore predicts 
effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012;43(5):1315-22. 
14. Shobha N, Buchan AM, Hill MD. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--
evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis. 
2011;31(3):223-8. 
15. Reid JM, Phillips SJ, Gubitz GJ, Jarrett J, Christian C, Dai D. A case-control study of tissue 
plasminogen activator for acute ischemic stroke. Can J Neurol Sci. 2007;34(4):411-6. 
16. Gladstone DJ, Black SE. Update on intravenous tissue plasminogen activator for acute stroke: 
from clinical trials to clinical practice. CMAJ. 2001;165(3):311-7. 
13 
 
17. Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute 
cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864-70. 
18. Hsueh IP, Lee MM, Hsieh CL. Psychometric characteristics of the Barthel activities of daily living 
index in stroke patients. J Formos Med Assoc. 2001;100(8):526-32. 
19. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 
1988;10(2):61-3. 
20. Duncan PW, Bode RK, Min Lai S, Perera S. Rasch analysis of a new stroke-specific outcome scale: 
the Stroke Impact Scale. Arch Phys Med Rehabil. 2003;84(7):950-63. 
21. Duncan PW, Lai SM, Tyler D, Perera S, Reker DM, Studenski S. Evaluation of proxy responses to 
the Stroke Impact Scale. Stroke. 2002;33(11):2593-9. 
22. Duncan PW, Reker DM, Horner RD, Samsa GP, Hoenig H, LaClair BJ, et al. Performance of a mail-
administered version of a stroke-specific outcome measure, the Stroke Impact Scale. Clin Rehabil. 
2002;16(5):493-505. 
23. Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ. The stroke impact scale 
version 2.0. Evaluation of reliability, validity, and sensitivity to change. Stroke. 1999;30(10):2131-40. 
24. Duncan PW, Wallace D, Studenski S, Lai SM, Johnson D. Conceptualization of a new stroke-
specific outcome measure: the Stroke Impact Scale. Top Stroke Rehabil. 2001;8(2):19-33. 
25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J 
Gen Intern Med. 2001;16(9):606-13. 
26. Williams LS, Brizendine EJ, Plue L, Bakas T, Tu W, Hendrie H, et al. Performance of the PHQ-9 as 
a screening tool for depression after stroke. Stroke. 2005;36(3):635-8. 
27. Wood-Dauphinee S, Williams JI. Reintegration to Normal Living as a proxy to quality of life. J 
Chronic Dis. 1987;40(6):491-502. 
14 
 
28. Wood-Dauphinee SL, Opzoomer MA, Williams JI, Marchand B, Spitzer WO. Assessment of global 
function: The Reintegration to Normal Living Index. Arch Phys Med Rehabil. 1988;69(8):583-90. 
29. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 
1957;2(5):200-15. 
30. Wolfe CD, Taub NA, Woodrow EJ, Burney PG. Assessment of scales of disability and handicap for 
stroke patients. Stroke. 1991;22(10):1242-4. 
31. Tilley BC, Marler J, Geller NL, Lu M, Legler J, Brott T, et al. Use of a global test for multiple 
outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke 
t-PA Stroke Trial. Stroke. 1996;27(11):2136-42. 
32. Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, et al. Medical 
complications after stroke: a multicenter study. Stroke. 2000;31(6):1223-9. 
33. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke. 
1996;27(3):415-20. 
34. Schmid AA, Yaggi HK, Burrus N, McClain V, Austin C, Ferguson J, et al. Circumstances and 
consequences of falls among people with chronic stroke. J Rehabil Res Dev. 2014;50(9):1277-86. 
35. Finestone HM, Guo M, O'Hara P, Greene-Finestone L, Marshall SC, Hunt L, et al. Driving and 
reintegration into the community in patients after stroke. PM R. 2010;2(6):497-503. 
36. Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement 
and accuracy. Med Care Res Rev. 2006;63(2):217-35. 
37. Ford AL, Williams JA, Spencer M, McCammon C, Khoury N, Sampson TR, et al. Reducing door-to-




38. Ifejika-Jones NL, Harun N, Mohammed-Rajput NA, Noser EA, Grotta JC. Thrombolysis with 
intravenous tissue plasminogen activator predicts a favorable discharge disposition in patients with 
acute ischemic stroke. Stroke. 2011;42(3):700-4. 
39. Kwon S, Hartzema AG, Duncan PW, Min-Lai S. Disability measures in stroke: relationship among 
the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale. Stroke. 
2004;35(4):918-23. 
40. Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on 
study validity. Pharmacoeconomics. 1999;15(3):241-56. 
41. Longobardi T, Walker JR, Graff LA, Bernstein CN. Health service utilization in IBD: comparison of 
self-report and administrative data. BMC Health Serv Res. 2011;11:137. 
42. Marshall R, Grayson D, Jorm A, O'Toole B. Are survey measures of medical care utilisation 
misleading? A comparison of self-reported medical care consumption with actual medical care 






Table 1.  Proportions of survey responders and non-responders across the hospital population 
 Completed Refused Recurrent 
stroke 
Deceased Unable to 
reach* 
Persons receiving tPA  
(n = 263) 
30% 22% 9% 6% 33% 
All persons with stroke or TIA 
n = 2901) 
26% 24% 5% 13% 32% 






Table 2.  Presenting characteristics for cases and controls 
 tPA group  
(n = 78) 
Control group 
(n = 156) 
P value 
NIHSS (median [IQR]) 5 [6] 3 [5] 0.002 
Age (yrs, mean ± SD) 65.1 ± 12.1 64.9 ± 13.3 0.88 
Gender  42% female 42% female 0.99 
Race  31% Afr. American 
69% Caucasian 
35% Afr. American 
65% Caucasian 
0.66 
Pre-morbid Barthel Index 
(mean ± SD) 
99 ± 4 98 ± 6 0.32 









Marital status  49% married/sig. other 
51% single/widowed 
57% married/sig. other 
43% single/widowed 
0.27 
Education level (yrs) 13.4 ± 2.5 12.6 ± 2.3 0.07 







Current or previous smoker  21% 22% 0.96 
Hypertension 53% 51% 0.95 
Coronary artery disease 19% 20% 0.98 
Atrial fibrillation 6% 8% 0.85 
Previous myocardial infarction 5% 8% 0.65 
Previous stroke or TIA 22% 28% 0.49 
NIHSS: National Institutes of Health Stroke Scale; TIA: transient ischemic attack 
*From clinical database 





Table 3.  Comparison of patient-reported outcome data.  Values are means ± SD unless otherwise 
indicated.   
 tPA group  Control group P value 
SIS Physical Function 80 ± 21 68 ± 26  0.0001 
SIS Cognition 81 ± 21 72 ± 26 0.001 
SIS Communication 87 ± 19 82 ± 23 0.008 
SIS Quality of Life/Participation 71 ± 29 62 ± 31 0.0005 
PHQ-9 5.3 ± 6.0 6.3 ± 6.2 0.043 
RNL 76 ± 20 72 ± 20 0.001 
Modified Rankin Scale (%) 0, 1 = 47% 
≥2 = 53% 
0,1 = 30% 
≥2 = 70% 
0.001 
Number of falls (%) 0 = 71% 
1 = 11% 
≥2 = 18% 
0 = 56% 
1 = 21% 
≥2 = 23% 
0.035 
Return to driving (%)* 69% 62% 0.20 
Return to work (%)*  50% 42% 0.28 
SIS: Stroke Impact Scale, range 0 – 100 with 100 = normal; PHQ-9: Patient Health Questionnaire, 9-item 
version quantifying depressive symptomotology, range = 0 – 27, with higher scores indicating worse 
symptoms; RNL: Reintegration to Normal Living index, quantifying satisfaction with abilities and 
converted to 0 – 100%, with higher scores = greater satisfaction.  
*Of the 196 people (62 tPA, 134 control) driving prior to the stroke, and of the 115 people (34 tPA, 81 





Table 4.  Comparison of self-reported healthcare utilization data.  Values are % indicated the service was 
used.   
  tPA group  Control group P value 
IRF stay 20% 31% 0.063 
SNF stay  4% 16% 0.006 
Home Health services 35% 36% 0.999 
Outpatient Rehabilitation services 30% 38% 0.150 
Physician office visits 1= 8% 
2-3 = 34% 
≥4 = 57% 
1 = 10% 
2-3 = 35% 
≥4 = 49% 
0.585 
Emergency Department visits 1 = 18% 
≥2 = 11% 
1 = 26% 
≥2 = 21% 
0.001 
Rehospitalization 22% 34% .040 
 
